Patents by Inventor Suvi Parviainen

Suvi Parviainen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Oncolytic adenoviruses coding for bi-specific antibodies and methods and uses related thereto
    Publication number: 20230272108
    Abstract: The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies of humans. More specifically, the present invention relates to an oncolytic adenoviral vector encoding a bispecific monoclonal antibody. Furthermore, the present invention relates to methods and uses utilizing the oncolytic adenoviral vectors, also together with adoptive cell therapies.
    Type: Application
    Filed: September 30, 2022
    Publication date: August 31, 2023
    Inventors: Akseli Hemminki, Suvi Parviainen, Siri Tähtinen, Ilkka Liikanen, Mikko Siurala
  • Oncolytic adenoviruses coding for bi-specific antibodies
    Patent number: 11485791
    Abstract: The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies of humans. More specifically, the present invention relates to an oncolytic adenoviral vector encoding a bispecific monoclonal antibody. Furthermore, the present invention relates to methods and uses utilizing the oncolytic adenoviral vectors, also together with adoptive cell therapies.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: November 1, 2022
    Assignee: TILT Biotherapeutics Oy
    Inventors: Akseli Hemminki, Suvi Parviainen, Siri Tähtinen, Ilkka Liikanen, Mikko Siurala
  • Oncolytic adenoviruses coding for bi-specific antibodies and methods and uses related thereto
    Publication number: 20180072809
    Abstract: The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies of humans. More specifically, the present invention relates to an oncolytic adenoviral vector encoding a bispecific monoclonal antibody. Furthermore, the present invention relates to methods and uses utilizing the oncolytic adenoviral vectors, also together with adoptive cell therapies.
    Type: Application
    Filed: March 17, 2016
    Publication date: March 15, 2018
    Inventors: Akseli Hemminki, Suvi Parviainen, Siri Tähtinen, Ilkka Liikanen, Mikko Siurala